Wearne Nicola, Botha Francois, Manning Kathryn, Price Brendon, Barday Zunaid, Post Frank A, Freercks Robert, Bertels Laurie, Mtingi-Nkonzombi Lungiswa, Muller Elmi
Division of Nephrology and Hypertension, Groote Schuur Hospital, University of Cape Town, Cape Town, South Africa.
Pathcare Laboratories, George, South Africa.
Transplantation. 2025 Jun 1;109(6):1038-1047. doi: 10.1097/TP.0000000000005271. Epub 2024 Nov 26.
The spectrum of histological findings in transplanted kidneys from HIV-positive donors to HIV-positive recipients is relatively unexplored. This study describes the type and timing of histological diagnoses observed in this unique cohort.
Adequate biopsies were analyzed at implantation and posttransplant between September 2008 and May 2022. Histological disease spectrum, distributions over time, and relevant clinical characteristics and management were reported for both for-cause and protocol biopsies.
Twenty-four implantation biopsies from 31 deceased donors and 179 allograft biopsies (100 for-cause, 79 protocol) from 50 recipients were analyzed. Most rejection episodes occurred in the first year posttransplant. Eighteen recipients (36%) had at least 1 episode of biopsy-confirmed acute/chronic T cell-mediated rejection (TCMR) or active antibody-mediated rejection (AMR). Protocol biopsies showed no active AMR or acute/chronic TCMR. However, 9 of 79 biopsies identified borderline/suspicious TCMR. Common nonrejection diagnoses were interstitial fibrosis and tubular atrophy, ascending pyelonephritis, and calcineurin inhibitor toxicity. Classic and suspected HIV-associated nephropathy (HIVAN) were identified in 3 and 6 patients, respectively. Protocol biopsies diagnosed 1 case of classic HIVAN and 6 cases of suspected HIVAN. AMR most adversely affected kidney function and significantly contributed to graft failure.
The histological findings in this cohort of HIV-positive kidney transplant recipients who received grafts from unmatched HIV-positive donors revealed a spectrum of abnormalities. Protocol biopsies added to surveillance on borderline rejection and assisted in the recognition of HIVAN. Confirmed rejection occurred in 18 recipients (36%). Understanding the factors contributing to this may assist in the optimization of immunosuppressive protocols in the future.
从HIV阳性供体移植到HIV阳性受体的肾脏组织学表现谱相对未被充分研究。本研究描述了在这一独特队列中观察到的组织学诊断类型和时间。
对2008年9月至2022年5月期间植入时和移植后的充分活检样本进行分析。报告了因病因活检和方案活检的组织学疾病谱、随时间的分布以及相关临床特征和管理情况。
分析了来自31名已故供体的24份植入活检样本以及来自50名受体的179份同种异体移植活检样本(100份因病因,79份方案活检)。大多数排斥反应发生在移植后的第一年。18名受体(36%)至少有1次活检确诊的急性/慢性T细胞介导的排斥反应(TCMR)或活动性抗体介导的排斥反应(AMR)。方案活检未显示活动性AMR或急性/慢性TCMR。然而,79份活检中有9份发现临界/可疑TCMR。常见的非排斥诊断为间质纤维化和肾小管萎缩、上行性肾盂肾炎以及钙调神经磷酸酶抑制剂毒性。分别在3例和6例患者中发现了典型和疑似HIV相关性肾病(HIVAN)。方案活检诊断出1例典型HIVAN和6例疑似HIVAN。AMR对肾功能的负面影响最大,并显著导致移植失败。
在这一接受来自不匹配HIV阳性供体肾脏移植的HIV阳性肾移植受者队列中,组织学表现显示出一系列异常。方案活检增加了对临界排斥的监测,并有助于识别HIVAN。18名受体(36%)发生了确诊的排斥反应。了解促成这一情况的因素可能有助于未来优化免疫抑制方案。